Following science to realise novel therapeutic opportunities
TES Pharma is a research-based biopharmaceutical company, located in Perugia (Italy), founded in 2011, focussed on the delivering first in class preclinical candidates for novel therapeutic targets.
TES Pharma is led by Prof. Roberto Pellicciari, inventor of Ocaliva® currently marketed by Intercept Pharmaceuticals for the treatment of Primary Biliary Cirrhosis (PBC). The company was founded by Prof. Pellicciari together with Drs. Antimo Gioiello, Antonio Macchiarulo, and Janet Robertson.
TES Pharma combines the academic passion for discovery with the focus, drive, and innovation of a research biotech.
The name of the company, TES, comes from the Etruscan word for “healing, curing, loving” that reflects both our dedication to provide novel and effective medicines and a link to the history of the region.